Chembio Diagnostics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Chembio Diagnostics, a leader in point-of-care diagnostics, announced participation in two investor conferences. The management team will attend the virtual 17th Annual Craig-Hallum Institutional Investor Conference on May 27, 2020, followed by the Benchmark Healthcare House Call Virtual Conference on June 16, 2020. Notably, these events do not include webcasts. Chembio specializes in diagnosing infectious diseases, leveraging its patented DPP technology for rapid testing. Their products cater to diverse markets including hospitals, clinics, and consumers.

News Market Reaction – CEMI

-4.58%

-4.58% Session move

In the trading session that priced this news, CEMI declined 4.58%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAUPPAUGE, N.Y., May 26, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the company plans to participate in two upcoming investor conferences.

Management is scheduled to participate in the virtual 17th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 27, 2020.

Management is also scheduled to participate in the Benchmark Healthcare House Call Virtual Conference on Tuesday, June 16, 2020. Due to the format of these events no webcasts are available.

About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.

DPP is Chembio’s registered trademark. For convenience, this trademark appears in this release without ® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.

Contact:  
Philip Taylor
Gilmartin Group
(415) 937-5406
investor@chembio.com

FAQ

What conferences will CEMI participate in May and June 2020?

CEMI will participate in the 17th Annual Craig-Hallum Institutional Investor Conference on May 27, 2020, and the Benchmark Healthcare House Call Virtual Conference on June 16, 2020.

Is there a webcast available for the CEMI investor conferences?

No, there are no webcasts available for the upcoming investor conferences attended by CEMI.

What technology does Chembio Diagnostics use for testing?

Chembio Diagnostics uses its patented DPP technology, which provides results in approximately 15 minutes using a small drop of blood.

What types of diseases does Chembio Diagnostics focus on?

Chembio Diagnostics focuses on diagnosing infectious diseases, including COVID-19, STDs, and tropical diseases.

Who can benefit from Chembio Diagnostics' products?

Chembio's products are used by hospitals, clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers worldwide.